Teva Pharmaceutical Industries Ltd
TEVA
Company Profile
Business description
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Contact
124 Dvora HaNevi’a Street
Tel Aviv6944020
ISRT: +972 39148213
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
32,842
Stocks News & Analysis
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
stocks
Takeover proposal agreed for ASX share, other offers permitted
Morningstar analysts’ take on the takeover for this undervalued industrial player.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.10 | 3.60 | -0.04% |
| CAC 40 | 8,142.08 | 77.06 | 0.96% |
| DAX 40 | 25,573.66 | 269.60 | 1.07% |
| Dow JONES (US) | 51,886.95 | 204.31 | 0.40% |
| FTSE 100 | 10,737.18 | 78.05 | 0.73% |
| HKSE | 25,042.71 | 291.93 | 1.18% |
| NASDAQ | 26,951.40 | 428.86 | 1.62% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,821.20 | 82.06 | 0.60% |
| S&P 500 | 7,729.11 | 78.61 | 1.03% |
| S&P/ASX 200 | 8,731.90 | 0.70 | 0.01% |
| SSE Composite Index | 3,949.91 | 38.04 | 0.97% |